糖皮质激素在肾小球肾炎中作用机制的研究
研究利用Pax8-Cre/GRfl/fl小鼠在肾上皮细胞特异性敲除糖皮质激素受体(GR),发现该操作可减轻肾毒性血清诱导的新月体肾炎,效果类似大剂量泼尼松龙,但无免疫抑制效应;体外实验显示泼尼松龙与米非司酮均直接抑制壁上皮细胞生长。
要点
- 肾上皮细胞特异性GR敲除可抑制新月体肾炎的白蛋白尿和细胞性新月体形成。
- GR敲除不产生泼尼松龙样的免疫抑制效应。
- GR拮抗剂米非司酮在野生型小鼠中减轻疾病效果不亚于大剂量泼尼松龙。
核心结论
- 糖皮质激素在新月体肾炎中直接作用于活化的肾小球壁上皮细胞。
- 糖皮质激素拮抗(米非司酮)是新月体肾炎的新治疗思路,效果至少不亚于大剂量泼尼松龙,且可能不良反应更少。
研究设计与样本
- 研究使用Pax8-Cre/GRfl/fl小鼠在肾上皮细胞特异性敲除糖皮质激素受体。
- 采用肾毒性血清诱导新月体肾炎(快速进展性肾小球肾炎)模型。
- 体外实验使用原代壁上皮细胞培养,并比较泼尼松龙与GR拮抗剂米非司酮的作用。
- 野生型小鼠中评估药理学GR拮抗剂米非司酮的治疗效果。
主要发现
- Pax8-Cre/GRfl/fl小鼠未表现出明显的自发表型。
- 在肾毒性血清诱导的新月体肾炎小鼠中,肾上皮细胞GR基因失活可抑制白蛋白尿和细胞性新月体形成,与对照小鼠接受大剂量泼尼松龙观察到的肾脏获益相似。
- 肾上皮细胞GR基因失活未诱导泼尼松龙所见的免疫抑制效应。
- 体外实验中,泼尼松龙和药理学GR拮抗剂米非司酮均直接作用于原代壁上皮细胞,抑制细胞向外生长和增殖。
- 在野生型小鼠中,药理学GR拮抗剂米非司酮减轻疾病的效果与大剂量泼尼松龙相当,且无全身免疫抑制效应。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
For several decades, glucocorticoids have been used empirically to treat rapid progressive GN. It is commonly assumed that glucocorticoids act primarily by dampening the immune response, but the mechanisms remain incompletely understood. In this study, we inactivated the glucocorticoid receptor (GR) specifically in kidney epithelial cells using Pax8-Cre/GRfl/fl mice. Pax8-Cre/GRfl/fl mice did not exhibit an overt spontaneous phenotype. In mice treated with nephrotoxic serum to induce crescentic nephritis (rapidly progressive GN), this genetic inactivation of the GR in kidney epithelial cells exerted renal benefits, including inhibition of albuminuria and cellular crescent formation, similar to the renal benefits observed with high-dose prednisolone in control mice. However, genetic inactivation of the GR in kidney epithelial cells did not induce the immunosuppressive effects observed with prednisolone. In vitro, prednisolone and the pharmacologic GR antagonist mifepristone each acted directly on primary cultures of parietal epithelial cells, inhibiting cellular outgrowth and proliferation. In wild-type mice, pharmacologic treatment with the GR antagonist mifepristone also attenuated disease as effectively as high-dose prednisolone without the systemic immunosuppressive effects. Collectively, these data show that glucocorticoids act directly on activated glomerular parietal epithelial cells in crescentic nephritis. Furthermore, we identified a novel therapeutic approach in crescentic nephritis, that of glucocorticoid antagonism, which was at least as effective as high-dose prednisolone with potentially fewer adverse effects.
引用
- Kuppe C, van Roeyen C, Leuchtle K, et al. Investigations of Glucocorticoid Action in GN. J Am Soc Nephrol. 2016. PMID: 27895155. doi:10.1681/ASN.2016010060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。